Dyne Therapeutics to Unveil One-Year Data for DM1 Drug in Key…

Event summary

Dyne Therapeutics will present one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at the World Muscle Society and AANEM meetings in late September 2026.
Data includes 6- and 12-month results from a pooled dose group (N=25-26) and a matched natural history cohort (N=41-46).
Topline data from the ACHIEVE registrational expansion cohort (REC) is expected in Q1 2027.
Z-basivarsen has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, as well as Orphan Drug designation from the EMA and MHLW in Japan.

The big picture

Dyne Therapeutics is advancing its lead candidate, z-basivarsen, through critical late-stage trials for Myotonic Dystrophy Type 1, a rare neuromuscular disease with significant unmet medical need. The upcoming data presentations come at a pivotal moment as the company prepares for potential regulatory submissions and seeks to differentiate its asset in a competitive landscape. The strategic focus on functional improvement aligns with broader industry trends toward targeted therapies for genetically driven diseases.

What we're watching

Regulatory Pathway: Whether the one-year data will support accelerated approval in the U.S. and other regulatory pathways.
Clinical Efficacy: The magnitude of functional improvement observed in the pooled dose group compared to the natural history cohort.
Market Positioning: How Dyne Therapeutics positions z-basivarsen against potential competitors in the DM1 treatment landscape.